By Claire Jeong, Director of Research, Asia BD, LSN
LSN is busily preparing for our largest conference of the year, RESI San Francisco, during JPM week on Tuesday, January 14th, 2020. In our last RESI SF conference, we had over 1,200 attendees join, making it our largest conference to date.
This time, we are featuring 3 tracks of panels and workshops that encompass a wide variety of sectors within life science and healthcare, including more specialized topics relevant to current industry trends. For the very first time, we are also dedicating an entire track for Featured Company Pitch Sessions, which will be a valuable opportunity for companies to showcase their technologies.
The ultimate goal of our panels and workshops is to provide valuable insights to fundraising early-stage companies, especially on how groups can effectively seek to work with investors and strategic partners. RESI strives to feature industry players from large VCs to new funds, from large corporations to angel investors, to lend their expertise to the entrepreneurs attending RESI. With excellent returning speakers and many new contributors, the panel lineup at this RESI is sure to be one of the best we’ve had.
For those who are already registered for RESI, we highly encourage you to attend some panels that are relevant to your company’s interests. If you’re interested in hearing from and meeting active industry experts, but haven’t registered, it’s not too late!
Without further ado, here are some of the panelists who will be joining our panels and workshops at RESI San Francisco:
 Chris Haskell VP, Head Open Innovation Center – North America West Bayer |
 Joyce Chan Director of External R&D Amgen |
 Anne Wellington Managing Director Cedars-Sinai Health Accelerator |
 Richard Proscia Senior Associate Providence Ventures |
 Brent Stackhouse Managing Director Mount Sinai Ventures |
 Wei Wu Senior Associate Illumina Ventures |
 Mike Ryan Co-Founder & CEO Bullet Point Network |
 Brent Ahrens General Partner Canaan Partners |
 Christina Takke Co-Founder & Managing Partner V-Bio Ventures |
 Roel Bulthuis Managing Director INKEF Capital |
 Claudia Karnbach Head of Business Development & Licensing, Oncology Bayer |
 David Cruikshank Partner ARCH Venture Partners |
 Dani Bach Partner +ND Capital |
 Bill Hyun Venture Partner Genoa Ventures |
 Chihiro Hosoya BD/VC Head Astellas Rx+ Business Accelerator |
 Ronald Dorenbos Head, Innovation Management & Scouting Takeda |
 Nicholas Mourlas Senior Director, New Ventures Johnson & Johnson |
 Gerry Brunk Managing Director Lumira Ventures |
 Neil Swami Principal Catalyst Health Ventures |
 Z Haroon Chairman and General Partner Julz Co LLC |
 Lauren Tyra Principal Scientist Green Park & Golf Ventures |
 Kwame Ulmer Venture Partner Wavemaker Three-Sixty Health |
 Diana Saraceni Founder and Managing Partner Panakes Partners |
 Ted Driscoll Managing Partner DigitalDx Ventures |
 Noel Jee Senior Associate Illumina Ventures |
 Sharon Chan Head of JLABS @Shanghai Johnson & Johnson |
 Weiyong Sun Senior Director, Specialty Medicine Search & Evaluation, Global Business Development Daiichi Sankyo |
 Lu Han Director of Business Development, Asia Pacific Lumira Ventures |
 Yao Li Ho Senior Director of Business Development LYFE Capital |
 Yanghuan Bao Investment Partner BOHE Angel Fund |
 Michelle Gon Partner McDermott Will & Emery Shanghai Offices |
 David Xu Chief Business Officer Viva Biotech |
 Frank Yan Operating Partner 3E Bioventures |
 Elona Baum Managing Director DEFTA Partners |
 Tad Weems Managing Director, Early Stage Partnerships Agilent Technologies |
 Jiwon Huh Director of Corporate Strategy Boryung Holdings |
 Lu Zhang Founder & Managing Partner Fusion Fund |
 Xinhong Lim Director Vickers Venture Partners |
 Yizhen Dong Principal 11.2 Capital |
 Miraj Sanghvi Principal DigiTx Partners |
Next Phase Newsletter 
Leave a Reply